Congress Asset Management Co. Has $2.92 Million Stock Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Congress Asset Management Co. raised its stake in Dynavax Technologies Co. (NASDAQ:DVAX) by 9.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 228,793 shares of the biopharmaceutical company’s stock after buying an additional 19,271 shares during the period. Congress Asset Management Co.’s holdings in Dynavax Technologies were worth $2,922,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of DVAX. Rhumbline Advisers raised its holdings in Dynavax Technologies by 4.7% in the 4th quarter. Rhumbline Advisers now owns 305,718 shares of the biopharmaceutical company’s stock valued at $3,904,000 after acquiring an additional 13,597 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new position in shares of Dynavax Technologies in the fourth quarter valued at approximately $71,000. Entropy Technologies LP increased its stake in shares of Dynavax Technologies by 17.2% during the fourth quarter. Entropy Technologies LP now owns 48,621 shares of the biopharmaceutical company’s stock worth $621,000 after purchasing an additional 7,121 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in Dynavax Technologies by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 27,873 shares of the biopharmaceutical company’s stock worth $356,000 after purchasing an additional 2,669 shares during the last quarter. Finally, KBC Group NV boosted its stake in Dynavax Technologies by 68.7% in the 4th quarter. KBC Group NV now owns 7,016 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 2,857 shares during the period. 96.96% of the stock is owned by institutional investors.

Dynavax Technologies Price Performance

Shares of NASDAQ DVAX opened at $12.82 on Tuesday. The business has a fifty day moving average price of $12.80 and a two-hundred day moving average price of $11.96. The stock has a market capitalization of $1.69 billion, a PE ratio of 98.62 and a beta of 1.32. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $13.89.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on DVAX. HC Wainwright increased their price objective on Dynavax Technologies from $29.00 to $31.00 and gave the stock a “buy” rating in a research report on Tuesday, January 14th. StockNews.com lowered shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th. Finally, The Goldman Sachs Group downgraded shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and cut their price objective for the company from $15.00 to $12.00 in a report on Tuesday, February 11th.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.